troglitazone has been researched along with Carcinogenesis in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tabatabaei Dakhili, SA | 1 |
| Pérez, DJ | 1 |
| Gopal, K | 1 |
| Haque, M | 1 |
| Ussher, JR | 1 |
| Kashfi, K | 1 |
| Velázquez-Martínez, CA | 1 |
1 other study available for troglitazone and Carcinogenesis
| Article | Year |
|---|---|
SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dr | 2021 |